NCT04056572View on ClinicalTrials.gov

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

PHASE2UnknownINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

October 30, 2021

Study Completion Date

April 30, 2022

Conditions
ALK-positive NSCLC
Interventions
DRUG

TQ-B3139

TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.

Trial Locations (2)

410013

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

510050

RECRUITING

Sun-Yat-Sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY